Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

Harjeet Singh(The University of Texas MD Anderson Cancer Center), Laurence J.N. Cooper(The University of Texas MD Anderson Cancer Center)
Cancer Research
May 11, 2011
10.1158/0008-5472.can-10-3843
Cited by 199

Related Papers

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
|Journal of Clinical Investigation|2016|499
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
|Proceedings of the National Academy of Sciences|2016|452
Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells
|PLoS ONE|2013|171
Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy
|Scientific Reports|2012|71